A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 13, 2013

Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission

CROI 2013A long-acting, injectable version of the antiretroviral dolutegravir prevented rectal transmission of simian HIV (SHIV) in eight macaques, the National AIDS Treatment Advocacy Project reports. Presenting their findings at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, investigators working in collaboration with GlaxoSmithKline (GSK) tested the nanoparticle-encased GSK1265744LAP (GSK744), which is a dolutegravir analog that has such a long half-life that monthly or even quarterly dosing is possible.

Eight macaques were given two injections of GSK744 as pre-exposure prophylaxis (PrEP), the first a week before exposure to SHIV and the second four weeks later. Another eight control macaques did not receive the injections. Then all of the primates were exposed rectally to SHIV each week for up to eight weeks.

All the macaques in the control group were infected with SHIV after a median two exposures, with a range of one to seven weeks. None of those who received the PrEP injections showed signs of infection during the eight weeks of exposures or for three weeks following. The investigators plan to continue monitoring all the macaques for at least 10 weeks after the last SHIV exposure.

All of the primates tolerated the drug well. The investigators concluded that GSK744 appears to be a promising avenue for PrEP among humans with either monthly or quarterly dosing. Considering that a major study of PrEP in African women recently failed because of adherence challenges, an agent requiring such infrequent dosing may be more in line with the needs of such a population and thus answer the problems that plagued that research.


To read the NATAP report, click here.

To read the conference abstract, click here

Search: simian HIV, SHIV, PrEP, pre-exposure prophylaxis, dolutegravir, macaque, National AIDS Treatment Advocacy Project, 20th Conference on Retroviruses and Opportunistic Infections, CROI, nanoparticle, anal exposure.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    Drew949
    South Orange County
    California


    soy_Ric
    Rochester
    New York


    youngbloodlatino
    Columbia
    Maryland


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.